GLP-1 Drugs Cut Heart Risks in 85,000 Older Adults as Reviews Flag 40% Lean-Mass Loss
Updated
Updated · Psychology Today · Aug 24
GLP-1 Drugs Cut Heart Risks in 85,000 Older Adults as Reviews Flag 40% Lean-Mass Loss
3 articles · Updated · Psychology Today · Aug 24
Summary
A 2025 meta-analysis of 11 randomized trials involving more than 85,000 people found GLP-1 drugs reduced major cardiovascular events, cardiovascular death and kidney complications in older adults.
A 2026 study in adults 80 and older with type 2 diabetes also linked GLP-1 therapy to fewer major cardiorenal events and lower all-cause mortality than older diabetes drugs.
Up to 40% of weight lost on GLP-1s can be lean mass, a sharper concern for seniors who already lose muscle faster; a 2026 review said measurable muscle loss appears consistently in the data.
Doctors and reviews cited in the report say the trade-off can be managed with supervision, protein intake and resistance training, while nausea, cost and insurance coverage remain practical hurdles.
Early research is also probing possible effects on inflammation, cognition and obesity-related cancers, but those benefits remain unproven and need larger, longer studies.